Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India.
J Drug Target. 2022 Aug;30(7):709-725. doi: 10.1080/1061186X.2022.2056188. Epub 2022 Mar 28.
Various preclinical and clinical studies exhibited the potential of cannabis against various diseases, including cancer and related pain. Subsequently, many efforts have been made to establish and develop cannabis-related products and make them available as prescription products. Moreover, FDA has already approved some cannabis-related products, and more advancement in this aspect is still going on. However, the approved product of cannabis is in oral dosage form, which exerts various limitations to achieve maximum therapeutic effects. A considerable translation is on a hike to improve bioavailability, and ultimately, the therapeutic efficacy of cannabis by the employment of nanotechnology. Besides the well-known psychotropic effects of cannabis upon the use at high doses, literature has also shown the importance of cannabis and its constituents in minimising the lethality of cancer in the preclinical models. This review discusses the history of cannabis, its legal aspect, safety profile, the mechanism by which cannabis combats with cancer, and the advancement of clinical therapy by exploiting nanotechnology. A brief discussion related to the role of cannabinoid in various cancers has also been incorporated. Lastly, the information regarding completed and ongoing trials have also been elaborated.
各种临床前和临床研究表明，大麻具有治疗多种疾病的潜力，包括癌症和相关疼痛。随后，人们做出了许多努力来建立和开发与大麻相关的产品，并将其作为处方产品提供。此外，FDA 已经批准了一些大麻相关产品，这方面的更多进展仍在继续。然而，大麻的批准产品为口服剂型，这对实现最大治疗效果有各种限制。通过采用纳米技术，大麻的生物利用度和最终治疗效果有了相当大的提高。除了高剂量使用大麻时众所周知的精神作用外，文献还表明大麻及其成分在减少临床前模型中癌症的致命性方面的重要性。本文综述了大麻的历史、法律方面、安全性概况、大麻对抗癌症的机制以及利用纳米技术进行临床治疗的进展。还简要讨论了大麻素在各种癌症中的作用。最后，还详细阐述了已完成和正在进行的试验的相关信息。
